BioMar delivered its strongest quarter on record for feed volumes and EBIT in Q3 2026. It sold 488,000 tonnes of feed, up 5% on the same period last year. Revenue reached DKK 5,807 million — around €777 million — and EBIT rose to DKK 618 million — around €83 million.

Volume growth extended across all three feed business segments: Salmon volumes increased by 4%, while Shrimp and Selected Species each grew by 7%. In the first nine months, Shrimp volumes rose by 17% and Selected Species by 8%, while Salmon volumes remained broadly in line with 2025.

“We delivered our strongest quarter ever in terms of volumes and EBIT,” said Carlos Diaz, BioMar’s chief executive. He linked the results to the expected increase in marine ingredient prices, mainly driven by El Niño, and said the company remained positive about medium-term market fundamentals.

EBIT performance varied across the segments. Salmon was the main driver of the quarterly improvement, and EBIT also increased in Selected Species. In contrast, EBIT in the Shrimp segment fell by 51%. BioMar attributed the decline to sharply higher raw material costs and low shrimp prices in Ecuador, which limited its ability to recover those costs.

Quarterly revenue rose by 19%, reflecting higher volumes and raw material prices, particularly fish oil and fishmeal. Exchange rate movements also had a positive impact of DKK 228 million. BioMar also highlighted its sourcing flexibility and ability to adapt feed formulations.

Following its strong performance in the first nine months, the company raised its revenue and EBIT guidance for 2026 while lowering its volume target. 

BioMar expects demand to be weaker than previously anticipated in some salmon and shrimp markets in the fourth quarter, particularly in Ecuador, where uncertainty around the electricity supply could lead to temporary production stoppages. The company also expects marine ingredient prices to remain high, partly because Peru’s second fishing quota was cancelled. It said some of the temporary raw material market conditions that supported quarterly profitability may not persist.

BioMar is continuing with its investment programme and expects new production lines in Ecuador and China to be commissioned during the fourth quarter.